Clinical Trial VICCGI1211


Phase IB/II Study of Induction Chemotherapy with XELOX, followed by Radiation Therapy, Carboplatin and RAD001 in Patients with Esophageal Cancer

Principal Investigator(s)

Bapsi Chak


  • Protocol No. VICCGI1211
  • Open Date: 03/08/2013
  • Staging: Phase I/II
  • Age Group: Adults
  • Scope: National
  • Objective: Phase I - Determine the MTD and DLT of RAD001 in combination with fixed dose weekly carboplatin administered for up to 6 weekly treatments, and radiation therapy after induction therapy with XELOX Phase II - Determine the rate of pathologic complete remission after the same treatment.
  • Disease Sites: Esophageal
  • Therapies: Chemotherapy - cytotoxic; Molecular Targeted Agents / Immunotherapy / Biologics; Radiotherapy
  • Drugs: Carboplatin; Oxaliplatin; RAD001; Xeloda (Capecitabine)
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01490749
  • Secondary Protocol No: CRAD001CUS159T



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.